Table 2. ORs (95% CI) for type 1 and type 2 diabetes and interquartile range increase (i.e., participants in the 75th vs. 25th percentiles) in measures of arsenic species in plasma

	75th vs. 25th percentile*	Type 1 diabetes			Type 2 diabetes		
		Model 1 OR (95% CI)	Model 2 OR (95% CI)	Model 3 OR (95% CI)	Model 1 OR (95% CI)	Model 2 OR (95% CI)	Model 3 OR (95% CI)
Concentrations of arsenic species							
∑As (ng/L)	110.3 vs. 63.8	0.89 (0.72, 1.11)	0.90 (0.71, 1.13)	0.88 (0.69, 1.12)	0.93 (0.68, 1.27)	1.04 (0.66, 1.64)	1.03 (0.66, 1.62)
iAs (ng/L)	63.1 vs. 40.7	0.87 (0.75, 1.01)	0.85 (0.73, 1.00)	0.84 (0.71, 0.99)	0.84 (0.67, 1.06)	0.94 (0.69, 1.28)	0.93 (0.69, 1.27)
MMA (ng/L)	13.9 vs. 4.2	1.21 (0.94, 1.54)	1.21 (0.93, 1.57)	1.22 (0.93, 1.60)	1.23 (0.87, 1.75)	1.06 (0.63, 1.77)	1.03 (0.62, 1.73)
DMA (ng/L)	30.1 vs. 13	1.14 (0.93, 1.39)	1.15 (0.94, 1.42)	1.15 (0.92, 1.43)	1.17 (0.88, 1.55)	1.14 (0.74, 1.75)	1.13 (0.73, 1.73)
Arsenic metabolism biomarkers							
iAs%	74 vs. 51.2	0.74 (0.57, 0.96)	0.70 (0.53, 0.92)	0.68 (0.50, 0.91)	0.68 (0.47, 0.98)	0.81 (0.48, 1.36)	0.82 (0.48, 1.39)
MMA%	14.9 vs. 6.3	1.27 (1.00, 1.60)	1.29 (1.01, 1.65)	1.33 (1.02, 1.74)	1.42 (1.01, 2.00)	1.11 (0.67, 1.85)	1.09 (0.65, 1.82)
DMA%	33.5 vs. 18.6	1.21 (0.97, 1.49)	1.27 (1.01, 1.58)	1.28 (1.01, 1.63)	1.25 (0.94, 1.66)	1.17 (0.78, 1.76)	1.17 (0.77, 1.77)

Model 1 is unadjusted; model 2 adjusted for age at visit (years), sex, BMI, parental educational level, and race; model 3 further adjusted for total folate and vitamin B12 levels.

*75th and 25th percentiles of each arsenic variable distribution were among control participants.